Video

(AAO) Considerations when using anti-VEGF for treating AMD

Author(s):

OT Staff Reports
Conferences|AAO

Prof. Giovanni Staurenghi, chairman of the University Eye Clinic, Department of Biomedical and Clinical Sciences at the University of Milan’s Luigi Sacco Hospital, Italy, discusses his presentation from this year's AAO, including findings from the HARBOR study of macular atrophy in AMD patients treated with ranibizumab.


Prof. Giovanni Staurenghi, chairman of the University Eye Clinic, Department of Biomedical and Clinical Sciences at the University of Milan’s Luigi Sacco Hospital, Italy, discusses his presentation from this year's AAO, including findings from the HARBOR study of macular atrophy in AMD patients treated with ranibizumab.

Related Videos
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Vikas Chopra, MD, at AAO 2024: The role of MIGS in earlier intervention and safer techniques
AAO 2024: Weijie Violet Lin, MD, discusses risk factors for epithelium-off cross-linking
Related Content
USC researchers receive $6 million CIRM grant to advance novel dry AMD therapy
November 21st 2024

USC researchers receive $6 million CIRM grant to advance novel dry AMD therapy

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Study examines the use of AI–based detection of diabetic retinopathy in the US
November 13th 2024

Study examines the use of AI–based detection of diabetic retinopathy in the US

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

Researchers offer insights into wet AMD: Study reveals potential to enhance anti-VEGF therapy with experimental drug to preserve vision
November 8th 2024

Researchers offer insights into wet AMD: Study reveals potential to enhance anti-VEGF therapy with experimental drug to preserve vision

FDA grants fast track status to FELIQS’ FLQ-101 for ROP
November 6th 2024

FDA grants fast track status to FELIQS’ FLQ-101 for ROP

© 2024 MJH Life Sciences

All rights reserved.